ReviewJournal of thrombosis and thrombolysis2021
Anticoagulant treatment in COVID-19: a narrative review.
Review in Journal of thrombosis and thrombolysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.
- Pooled it
- Clinical Features of Central Nervous System Complications Caused by the SARS-CoV-2 Omicron Variant.Immunity, inflammation and disease · 2025Article
- The Role of Sterile Inflammation in Thrombosis: Consequences for Cardiovascular Disease and COVID-19.Mediators of inflammation · 2025Review
- Effectiveness of Drug Repurposing and Natural Products Against SARS-CoV-2: A Comprehensive Review.Clinical pharmacology : advances and applications · 2024Review
- Interrelationship between COVID-19 and Coagulopathy: Pathophysiological and Clinical Evidence.International journal of molecular sciences · 2023Review
- IL1RA mediated the effects of aspirin on COVID-19 severity: A Mendelian randomization study.The Journal of infection · 2023Article
- Neurological Manifestations of hospitalized patients with mild to moderate infection with SARS-CoV-2 Omicron variant in Shanghai, China.Journal of infection and public health · 2023Article
- A snake venom-analog peptide that inhibits SARS-CoV-2 and papain-like protease displays antithrombotic activity in mice arterial thrombosis model, without interfering with bleeding time.Thrombosis journal · 2023Article
- Strategies Tackling Viral Replication and Inflammatory Pathways as Early Pharmacological Treatment for SARS-CoV-2 Infection: Any Potential Role for Ketoprofen Lysine Salt?Molecules (Basel, Switzerland) · 2022Review
- Anticoagulation failure in pulmonary thromboembolism in COVID-19 pneumonia despite prolonged anticoagulation: A case series.Annals of medicine and surgery (2012) · 2022Article
- Mucolytic and Antioxidant Properties of Carbocysteine as a Strategy in COVID-19 Therapy.Life (Basel, Switzerland) · 2022Review
- Review
- Retroperitoneal hematoma in patients with COVID-19 infection during anticoagulant therapy: A case series and literature review.The Journal of international medical research · 2022Review
- Exploring the Role of Krebs von den Lungen-6 in Severe to Critical COVID-19 Patients.Life (Basel, Switzerland) · 2022Article
- Acute Progressive retro-peritoneal hematoma in COVID19 patients with sub cutaneous ecchymosis.Annals of medicine and surgery (2012) · 2022Article
- Acute retroperitoneal hematoma following severe Covid-19 and the use of anticoagulants.Annals of medicine and surgery (2012) · 2022Article
- COVID-19 coagulopathy and antiphospholipid syndrome.Revista colombiana de reumatologia · 2022Review
- Left ventricular thrombosis and endogenous endophthalmitis in the setting of COVID-19: A case report.Clinical case reports · 2022Article
- Untapping host-targeting cross-protective efficacy of anticoagulants against SARS-CoV-2.Pharmacology & therapeutics · 2022Review
- COVID-19's impact on lung tissue: A case report.International journal of surgery case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The actual Coronavirus Disease (COVID 19) pandemic is due to Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the coronavirus family. Besides the respiratory involvement, COVID 19 patients frequently develop a pro-coagulative state caused by virus-induced endothelial dysfunction, cytokine storm and complement cascade hyperactivation. It is common to observe diffuse microvascular thrombi in multiple organs, mostly in pulmonary microvessels. Thrombotic risk seems to be directly related to disease severity and worsens patients' prognosis. Therefore, the correct understanding of the mechanisms underlying COVID-19 induced prothrombotic state can lead to a thorough assessment of the possible management strategies. Hence, we review the pathogenesis and therapy of COVID 19-related thrombosis disease, focusing on the available evidence on the possible treatment strategies and proposing an algorithm for the anticoagulation strategy based on disease severity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.